¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¼ö»óÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ
¸ðüžÆÀÇÇР/   ºÎÀÎÁ¾¾çÇР /   »ý½Ä³»ºÐºñÇР /   ÀϹݺÎÀΰúÇÐ
Æ÷½ºÅÍ : ºÎÀÎÁ¾¾çÇÐ - ÀϽà : 2017³â 9¿ù 22ÀÏ(±Ý) ~ 2017³â 9¿ù 23ÀÏ(Åä)
- Àå¼Ò : EXHIBITION HALL B[1F]
(08:00~17:00)
3008:00~08:00 °­ÀçÈ«
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer: A propensity-score matching study
3108:00~08:00 ±è¹Ì¼±
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Safety analysis of negative margins after conization in the patients with microinvasive squamous cell carcinoma of uterine cervix
3208:00~08:00 ±è¹Ì¼±
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Uterine involvement in epithelial ovarian cancer with preoperative and intraoperative tumor-free uterus: the rationale of uterus-conserving staging operation
3308:00~08:00 ±è»óÀÏ
°¡Å縯ÀÇ´ë ¼ººó¼¾Æ®º´¿ø »êºÎÀΰú
Biomarker utility of the E2/E6 ratio and L1 immunoreactivity for determining HPV16-positive ¡ÃCIN2 lesions and cervical squamous cell carcinoma
3408:00~08:00 ±è»óÀÏ
°¡Å縯ÀÇ´ë ¼ººó¼¾Æ®º´¿ø »êºÎÀΰú
The relationship between Ureaplasma species and cervical intraepithelial neoplasia in 1 asymptomatic sexually active persons
3508:00~08:00 ±è¼º¹Î
°í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú
The comparison of surgical outcomes and learning curves of radical hysterectomy by laparoscopy and robotic system for cervical cancer: An experience of a single surgeon
3608:00~08:00 ±è¼¼ÀÍ
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Impact of BRCA mutational status on clinical outcome in advanced-stage high-grade serous ovarian cancer
3708:00~08:00 ±èÁöȯ
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Comparison of surgical outcomes and 2-year disease progression free survival rate between single-port access staging laparoscopy and conventional staging laparoscopy in uterine cancer
3808:00~08:00 ±èÇýÀÎ
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
The effect of PD-L1 and PD-L2 expression on the prognosis of ovarian cancer patients: A meta analysis
3908:00~08:00 ±èÈñÁ¤
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Serum Long non-coding RNA expression Profiles in Ovarian Cancer
4008:00~08:00 ³ë¾Æ¹Ì
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú
Epigenetic modification of ¥á-N-acetylgalactosaminidase (NAGA) enhances cisplatin resistance in ovarian cancer
4108:00~08:00 ¹Ú¼±Èñ
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Surgical Apgar Score in Patients Undergoing Robotic Surgery for Cervical Cancer
4208:00~08:00 ¼­ÁØÇü
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Basal characteristics and survival between BRCA-associated ovarian cancer and BRCA-negative ovarian cancer
4308:00~08:00 ¼­ÁØÇü
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis
4408:00~08:00 ¼Ò°æ¾Æ
´Ü±¹´ëÇб³º´¿ø »êºÎÀΰú
Risk factors of persistent HPV infection after treatment for high-grade squamous intraepithelial lesion
4508:00~08:00 ¼Õ°æ¾Æ
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Differences in correlation of Progression-Free Survival and Overall Survival by clinical variables in epithelial ovarian cancer
4608:00~08:00 ½Å¿ø±³
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
4708:00~08:00 ¿À¼Ò¶ó
µ¿¾Æ´ëÇб³º´¿ø »êºÎÀΰú
Comparison of four malignancy risk indices in the preoperative discrimination between invasive ovarian cancer and borderline ovarian tumor
4808:00~08:00 ¿Õ¿µ¹Ì
¿¬¼¼´ëÇб³ ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø »êºÎÀΰú
Overexpression of mir-944 as a prognostic biomarker in cervical cancer
4908:00~08:00 À¯Áö±Ù
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Incidence and prognosis of ovarian clear cell carcinoma in surgically resected endometrioma.
5008:00~08:00 À̼±¿µ
ÀüºÏ´ëÇб³º´¿ø ¹æ»ç¼±Á¾¾çÇаú
¿©¼º¾Ï¿¡¼­ÀÇ Áø´Ü¸¶Ä¿¿Í Ç÷¾×¼øȯÁ¾¾ç ¼¼Æ÷ÀÇ »ó°ü°ü°è ºÐ¼® ¹× »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß±¼À» À§ÇÑ ¼±Ç࿬±¸
5108:00~08:00 À̼¼¿µ
°í·ÁÀÇ´ë ¾È»êº´¿ø »êºÎÀΰú
CA125 Á¤»ó ȯÀÚ±º¿¡°Ô¼­ HE4 Áõ°¡´ëÇÑ ¿øÀÎ ºÐ¼®
5208:00~08:00 À̽ÂÇö
µ¿¾Æ´ëÇб³º´¿ø »êºÎÀΰú
Lymphovascular space invasion as a prognostic factors for disease recurrence in patients with early endometrioid endometrial cancer
5308:00~08:00 ÀÌ¿µÀç
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Preliminary data of Next Generation Sequencing using AMC panel in gynecologic cancer patients
5408:00~08:00 ÀÌÇýÁÖ
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Clinical characteristics and outcomes of placental site trophoblastic tumor: Experience of single institution in Korea
5508:00~08:00 Àå½Å¾Æ
ÀÎÇÏ´ëÇб³º´¿ø »êºÎÀΰú
Subtyping HPV from the tissue of uterine cervix at an institution
5608:00~08:00 ÀåűÔ
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Clinical significance of atypical glandular cells in cervical Pap smears : An analysis of 529 cases at a single institution
5708:00~08:00 Á¤¿µ½Å
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy in advanced-stage ovarian cancer: A single institution retrospective review
5808:00~08:00 ÁÖ¿ìö
È­¼ø Àü³²´ëÇб³º´¿ø »êºÎÀΰú
Can a surgery be avoided? Diagnosis and antibiotic treatment for the adnexal actinomycosis mimicking an advanced ovarian cancer
5908:00~08:00 ÁÖ¿ìö
È­¼ø Àü³²´ëÇб³º´¿ø »êºÎÀΰú
HPV genotype as predictor of disease progression in women with biopsy-proven negative or CIN1 of atypical squamous cell of undetermined significance (ASC-US)
6008:00~08:00 Â÷°æ¼±
°¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú
Multiple Allele sequence in MICA influence susceptibility to cervical cancer in a Korean population
6108:00~08:00 ÃÖÁöÈñ
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Preoperative serum cancer antigen 125(CA125) to carcinoembryonic antigen(CEA) ratio may differentiate mucinous carcinoma from other epithelial ovarian cancers
6208:00~08:00 ÇÏÇüÀÎ
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø »êºÎÀΰú
A Clinico-pathologic review of uterine Smooth muscle Tumor of Uncertain Malignant Potential (STUMP) in single institution
6308:00~08:00 È«¾Æ¸§
ÀüºÏ´ëÇб³º´¿ø »êºÎÀΰú
The role of SIRT6 expression in ovary cancer: association with epithelial to mesenchymal transition
6408:00~08:00 È«Áö¿µ
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Comparing efficacy between bevacizumab, paclitaxel, carboplatin triplet and combination chemotherapy in recurrent cervical cancer:single center experience
6508:00~08:00 È«ÁøÈ­
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
Programmed cell death protein-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization
6608:00~08:00 ȲÀºÁö
ÇѸ²ÀÇ´ë °­³²¼º½Éº´¿ø »êºÎÀΰú
Is Previous Cesarean Section a Risk Factor for Developing Adenomyosis?
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ - ÀϽà : 2017³â 9¿ù 22ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F]
GO1-GO5 (08:20~09:10) ÁÂÀå : ±è¿µÅÂ(¿¬¼¼ÀÇ´ë)
GO108:20~08:30 Á¶ÀçÇö
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Optimal tumour size for stage IB1-IIA2 cervical cancer : MRI vs Pathology vs colposcopy
GO208:30~08:40 ¿À¼öÇö
ÀüºÏ´ëÇб³º´¿ø »êºÎÀΰú
Increase in sub-tumor temperature and blood flow in cervical carcinoma by heating with modulated electro-hyperthermia(mEHT)
GO308:40~08:50 ¾î°æÁø
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Two-step sentinel lymph node mapping strategy in endometrial cancer using fluorescent imaging: a pilot observational study
GO408:50~09:00 ÀÌ°Ç¿ì
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Effectiveness of Sentinel Lymph Node Mapping: Comparison with MRI, PET/CT in early cervical and endometrial cancer surgery
GO509:00~09:10 ±è¹Ì¼±
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Adjuvant therapy for improving survival outcomes in women with uterine-confined endometrial cancer of endometrioid grade 3, serous papillary and clear cell histology: A multicenter study
GO6-GO10 (09:10~10:00) ÁÂÀå : ±èÀç¿ø(¼­¿ïÀÇ´ë)
GO609:10~09:20 ÀÌ¿ëÀç
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer
GO709:20~09:30 ¹Ú¼öÁø
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Asian perspective on the quality of debulking surgery for advanced-stage ovarian cancer: Results of an international survey
GO809:30~09:40 ³ëÁØÈ£
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Comparison of RNA-seq and microarray of gene expression signatures as a predictor of survival in six selected cancers
GO909:40~09:50 ¾î°æÁø
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Mutated exon level in BRCA1 may influence the clinical course of BRCA1-mutated epithelial ovarian cancer
GO1009:50~10:00 ¼³¾Ö¶õ
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Genomic landscape of ovarian clear cell carcinoma via next generation sequencing cancer
GO11-GO15 (10:30~11:20) ÁÂÀå : ±è¿ë¹ü(¼­¿ïÀÇ´ë)
GO1110:30~10:40 ±Çº´¼ö
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
The role of microRNA-424/503-WEE1 axis in ovarian cancer stem like cells
GO1210:40~10:50 ±è¹Ì¼±
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Identification of histology-specific expression of HOX genes and tailored strategy for overcoming the resistance to platinum in epithelial ovarian cancer
GO1310:50~11:00 Ȳµ¿¿ø
ÀÎÁ¦ÀÇ´ë ÀÏ»ê¹éº´¿ø »êºÎÀΰú
Ketone body suppresses human ovarian cancer via modulation of mammalian target of rapamycin: A pilot study
GO1411:00~11:10 ¿À¼öÇö
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Maspin expression related with hypoxia affects prognosis of clear cell carcinoma of the ovary
GO1511:10~11:20 À±°¡¿µ
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
Long Interspersed Element-1 Open Reading Frame 1 Protein Expression Profiles in Ovarian Cancers
GO16-GO20 (11:20~12:10) ÁÂÀå : ±è±âÇü(ºÎ»êÀÇ´ë)
GO1611:20~11:30 ±èÁöȯ
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy.
GO1711:30~11:40 Á¤ÈñÁ¤
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Low value of staging procedure in detecting omental and peritoneal occult metastasis in mucinous borderline ovarian tumors
GO1811:40~11:50 ¾öÁ¤¹Î
ÇѾç´ëÇб³º´¿ø »êºÎÀΰú
Optimal debulking surgery including systemic pelvic and para-aortic lymphadenectomy, is it possible during laparoscopic interval debulking surgery after neoadjuvant chemotherapy in ovarian cancer​?
GO1911:50~12:00 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Anti-cancer effect of axitinib in ovarian cancer
GO2012:00~12:10 ¿Á±¸½½
¿øÀÚ·ÂÀÇÇпø »êºÎÀΰú
Role of radiation therapy in recurrent ovarian cancer
GO21-GO24 (12:10~12:50) ÁÂÀå : ¼º¼®ÁÖ(Â÷ÀÇ°úÇдë)
GO2112:10~12:20 ±èÀ±Áö
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Pretreatment neutrophil-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer
GO2212:20~12:30 ÀÌÀÎÇÏ
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
External validation of dynamic change of CA-125 as a predictive and prognostic in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy
GO2312:30~12:40 Á¶Çö³ç
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
Prognostic value of preoperative lymphocyte-monocyte ratio in elderly patients with advanced epithelial ovarian cancer
GO2412:40~12:50 ÇÑ¿µÁö
¼º±Õ°üÀÇ´ë °­ºÏ»ï¼ºº´¿ø »êºÎÀΰú
The survival analysis of advanced stage epithelia ovarian / fallopian tube / primary peritoneum carcinoma according to performance of high complexity upper abdominal surgery
GO25-GO28 (14:00~14:40) ÁÂÀå : ÀÌÁ¾ÇÐ(°æ»óÀÇ´ë)
GO2514:00~14:10 À̾ƶó
°¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú
Risk factors of diagnostic discrepancy between colposcopically directed biopsies and loop electrosurgical excision procedure conization of the uterine cervix
GO2614:10~14:20 º¯Á¤¹Ì
ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú
The clinical significance of a pattern-based classification system in management of endocervical adenocarcinoma
GO2714:20~14:30 È«¾Æ¸§
ÀüºÏ´ëÇб³º´¿ø »êºÎÀΰú
Insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) as biomarkers in women with cervical cancer or cervical dysplasia
GO2814:30~14:40 ±è¹Î°æ
Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer
GO29-GO32 (14:40~15:20) ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë)
GO2914:40~14:50 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Machine Learning-guided Staging in Patients with Epithelial Ovarian Cancer
GO3014:50~15:00 ½ÅÁ¤¾ð
Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
Robot (Xi) assisted transperitoneal infrarenal lymphadenectomy by Vessel sealer robot instrument
GO3115:00~15:10 ÀÌÀººñ
°è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú
Robotic single site versus robotic multiport radical hysterectomy c pelvic node dissection in early cervical cancer : a case control study
GO3215:10~15:20 ¾öÁ¤¹Î
ÇѾç´ëÇб³º´¿ø »êºÎÀΰú
Impact of morcellation on recurrence of patients with cellular leiomyoma after laparoscopic myomectomy
GO33-GO37 (15:20~16:10) ÁÂÀå : ±è¿µÅ¹(¿ï»êÀÇ´ë)
GO3315:20~15:30 ±è¼±¾Æ
Clinical outcome of high-grade cervical intraepithelial neoplasia during pregnancy: A 10-year experience
GO3415:30~15:40 ±èÇüÁÖ
¿øÀÚ·ÂÀÇÇпø »êºÎÀΰú
Young age is associated with aggressive feature, radioresistance, and relative lymphopenia in cervical cancer
GO3515:40~15:50 ±èÇý°æ
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Evaluation of the pelvic autonomic nerve function and quality of life related with the pelvic organs after type C1 hysterectomy in patients with early-stage cervical cancer
GO3615:50~16:00 Àå°æÁø
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Clinical characteristics of long-term ovarian cancer survivors: A study of prognostic inflection points for long-term survivorship in advanced epithelial ovarian cancer
GO3716:00~16:10 ±è¹Ì¼±
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
A nomogram for predicting the risk of lower extremity lymphedema in patients undergoing lymphadenectomy for gynecologic cancers
GO38-GO42 (16:10~17:00) ÁÂÀå : ±è¼º¿±(Á¦ÁÖÀÇ´ë)
GO3816:10~16:20 ±èÁöÇý
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Preclinical trial of targeted agents using NGS and PDX models in Gyn Cancer
GO3916:20~16:30 ±èÁöÇý
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
The study about anti-cancer mechanism of tetraarsenic oxide in cervical cancer using cell line and PDX model
GO4016:30~16:40 Ãֽ¿µ
°í·ÁÀÇ´ë ¾È»êº´¿ø »êºÎÀΰú
³­¼Ò¾Ï, Àڱ󻸷¾Ï ȯÀÚÀÇ ±âÀúÁúȯ°ú HE4 °ªÀÇ ¿¬°ü¼º
GO4116:40~16:50 ±èÇÏ¿¬
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
The utility of MLH1 methylation test for Lynch syndrome screening in endometrial cancer patients
GO4216:50~17:00 ½ÅÁ¤¾ð
°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
Comparison of robotic-assisted versus laparoscopy for transperitoneal infrarenal paraaortic lymphadenectomy in patients with endometrial cancer